Interferon-beta responders and non-responders. A biological approach

Neurol Sci. 2008 Sep:29 Suppl 2:S216-7. doi: 10.1007/s10072-008-0941-2.

Abstract

The therapeutic benefits of interferon-beta are limited, as some patients with multiple sclerosis (MS) do not respond to therapy. Based on their biological characteristics, non-responsive patients can be divided into three subgroups: genetic, pharmacological and pathogenetic non-responders. In order to tailor the best treatment in both newly diagnosed MS patients and those already receiving treatment, the neurologist must carefully consider the risk of treating non-responders.

Publication types

  • Review

MeSH terms

  • Biomarkers / analysis
  • Drug Resistance / genetics
  • Drug Resistance / immunology*
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / genetics
  • Gene Expression Regulation / immunology
  • Humans
  • Immune Tolerance / drug effects
  • Immune Tolerance / genetics
  • Immune Tolerance / immunology
  • Immunologic Factors / pharmacology
  • Interferon-beta / pharmacology*
  • Multiple Sclerosis / diagnosis*
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / physiopathology
  • Receptor, Interferon alpha-beta / genetics
  • Receptor, Interferon alpha-beta / immunology
  • Tachyphylaxis / genetics
  • Tachyphylaxis / immunology
  • Treatment Outcome

Substances

  • Biomarkers
  • IFNAR1 protein, human
  • Immunologic Factors
  • Receptor, Interferon alpha-beta
  • Interferon-beta